Search research articles
Contact Us
Filters
Showing results (101-110 of 117) with videos related to
Page
of 12
Sort By:
The Lancet. Haematology
|
July 2, 2022
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial
Frank Cools, Saverio Virdone, Jitendra Sawhney, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis
|
February 3, 2021
Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE
Carlos Jerjes-Sánchez, David Rodriguez, Alfredo E Farjat, et al.
Thrombosis Research
|
December 24, 2022
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE
Alexander G G Turpie, Alfredo E Farjat, Sylvia Haas, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis
|
December 1, 2022
On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease
Sylvia Haas, Alfredo E Farjat, Karen Pieper, et al.
Journal of the American College of Cardiology
|
March 25, 2017
Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism
Stavros V Konstantinides, Eric Vicaut, Thierry Danays, et al.
Thrombosis and Haemostasis
|
September 24, 2021
Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial
Olivier Sanchez, Anaïs Charles-Nelson, Walter Ageno, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|
December 20, 2018
Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial
Stefano Barco, Mariaconcetta Russo, Eric Vicaut, et al.
Thrombosis and Haemostasis
|
December 7, 2017
Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study
Frederikus A Klok, Walter Ageno, Stefano Barco, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|
December 20, 2022
Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2
Anna C Mavromanoli, Stefano Barco, Walter Ageno, et al.
Research and Practice in Thrombosis and Haemostasis
|
July 19, 2021
Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin
Roisin Bavalia, Ingrid M Bistervels, Wim G Boersma, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 117) with videos related to
Sort By:
Page
of 12
The Lancet. Haematology
|
July 2, 2022
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial
Frank Cools, Saverio Virdone, Jitendra Sawhney, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis
|
February 3, 2021
Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE
Carlos Jerjes-Sánchez, David Rodriguez, Alfredo E Farjat, et al.
Thrombosis Research
|
December 24, 2022
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE
Alexander G G Turpie, Alfredo E Farjat, Sylvia Haas, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis
|
December 1, 2022
On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease
Sylvia Haas, Alfredo E Farjat, Karen Pieper, et al.
Journal of the American College of Cardiology
|
March 25, 2017
Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism
Stavros V Konstantinides, Eric Vicaut, Thierry Danays, et al.
Thrombosis and Haemostasis
|
September 24, 2021
Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial
Olivier Sanchez, Anaïs Charles-Nelson, Walter Ageno, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|
December 20, 2018
Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial
Stefano Barco, Mariaconcetta Russo, Eric Vicaut, et al.
Thrombosis and Haemostasis
|
December 7, 2017
Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study
Frederikus A Klok, Walter Ageno, Stefano Barco, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|
December 20, 2022
Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2
Anna C Mavromanoli, Stefano Barco, Walter Ageno, et al.
Research and Practice in Thrombosis and Haemostasis
|
July 19, 2021
Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin
Roisin Bavalia, Ingrid M Bistervels, Wim G Boersma, et al.
Page
of 12